Company intelligence / Profile preview

Gansu Fuzheng Pharmaceutical Technology

Gansu Sheng, Chinaen.sh-bahealpharma.com ↗

Ownership: Private
Development stage: Other

Overview

Zhenqi Fuzheng Capsule is being evaluated in a randomized phase II clinical trial as an adjunct to surgery/chemotherapy/radiotherapy for non-small cell lung cancer and nasopharyngeal carcinoma patients with Qi-Yin deficiency. The aim is to improve quality of life post-treatment; results pending as trial is recruiting.[1] A separate completed study evaluated the bioequivalence of afatinib maleate tablets produced by another company using their process—this was successful but does not represent novel drug development by Gansu Fuzheng itself.[1]

Therapeutic areas: Women's HealthOncology
Modalities: Herbal medicineSmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Gansu Fuzheng Pharmaceutical Technology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Gansu Fuzheng Pharmaceutical Technology.

Explore the full profile